Omicron-targeting COVID boosters may be out after Labor Day, and Moderna has joined Pfizer and BioNTech in filing for authorization
admin Americans age 12 and older could begin getting omicron-specific COVID-19 boosters soon after Labor Day,…
Read MoreBNTX
Omicron-specific boosters could be rolled out after Labor Day: report
Americans age 12 and older could begin getting omicron-specific COVID-19 boosters soon after Labor Day,…
Read MorePfizer and BioNTech say data show COVID vaccine has more than 70% efficacy in small children, with cases now rising in just 7 states
Pfizer and German partner BioNTech on Tuesday offered updated COVID vaccine data supporting efficacy in…
Read MoreJill Biden leaves isolation after twice testing negative, and Novavax vaccine is now allowed for U.S. teens
First lady Jill Biden left isolation on Sunday, after testing negative for COVID twice and…
Read MoreWhat will insurance coverage of COVID-19 vaccines and treatments look like? The Biden administration is trying to figure that out
Get ready for a big change in how the U.S. will pay for COVID-19 vaccines…
Read MoreLarge-scale study finds COVID patients at higher risk of brain fog and psychosis after two years compared with other respiratory illnesses
People who have had COVID-19 are facing a higher risk of neurological and psychiatric conditions…
Read MoreU.K. regulator is first to authorize Moderna’s bivalent COVID booster for 18-and-older population
The U.K. regulator has become the first to authorize Moderna’s bivalent COVID vaccine booster for…
Read MoreBioNTech stock sinks more than 8% after profit, revenue fall below expectations
The U.S.-listed shares of Germany-based BioNTech SE BNTX, +1.48% sank 8.2% in premarket trading Monday,…
Read MoreOfficial U.S. tally of new cases may be declining, but at-home testing obscures data; Novavax opens trial of vaccine for very young children
The daily average of new U.S. cases may have started to decline based on official…
Read More
Get ready for more merger mania in pharma sector the rest of the year
Pfizer Inc.’s PFE, +0.45% $5.4 billion acquisition of Global Blood Therapeutics Inc. GBT, -0.02% is…
Read More